A car-t cell therapy trial for AML or MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that came back or did not respond to treatment, or MDS with at least 5% blast cells in your bone marrow.
- You are in fairly good physical condition (able to do daily activities without help).
- Your blood cell counts, kidney, liver, heart, and lung function are within certain safe levels.
- You have not had a stem cell transplant with active complications or certain other cancer treatments recently.
- You are willing to use birth control if needed and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients who have already received ARD103 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to monitor their health over time without giving any new treatment.
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
This trial tests a new treatment called CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatments. CAR-T cells are specially designed to find and destroy cancer cells. The goal is to see if this therapy is safe and works for patients whose cancer cells have specific markers (CD33, CD123, or CLL-1).
This trial tests a lab-made immune cell treatment (CAR T cells) that targets specific markers on acute myeloid leukemia cells. It aims to control the leukemia, but it also involves close monitoring because it is an early-phase study.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.